Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-Cell Response to Atabecestat in Alzheimer's Patients
NCT03587376Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Primary completion
- Aug 2018
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 1, open-label trial of atabecestat in Alzheimer's disease (AD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants with Atabecestat-Specific T-cell Mediated Inflammatory Immune Response at Day 1. Started May 2018; status: completed.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03587376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03587376.